The 1.2 million 1 shot treatment is called chimeric antigen receptor T cell therapy, or CAR-T therapy for short, and is currently mainly used in the treatment of hematologic malignancies such as lymphoma, excluding advanced liver cancer. CAR-T therapy is a kind of cellular immunotherapy, which is to genetically modify the tumor patient’s own T cells through gene editing and other technologies, so as to make the T cells express a series of antigen receptors on their surface, and then enhance the killing ability of T cells against malignant tumor cells. There have been studies confirming the good effect of CAR-T therapy on hematologic malignancies such as B-lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma. Hepatocellular carcinoma belongs to solid malignant tumors, and the main treatment modalities for patients with advanced hepatocellular carcinoma include surgical resection, liver transplantation, radiofrequency ablation therapy, arterial embolization chemotherapy, and targeted therapy, etc. However, there are still many difficulties in the use of CAR-T therapy for solid tumors, and there is no relevant drug available yet. Cellular immunotherapy still has great application prospects in the treatment of solid tumors, and there are many researches actively exploring it, and it is believed that more treatments will emerge with the progress of science to bring hope to patients with advanced hepatocellular carcinoma.